Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension

In this open-label study, we evaluated the effect of upfront macitentan and riociguat combination in newly diagnosed pulmonary arterial hypertension (PAH) patients. In 15 consecutive PAH patients, we collected clinical and hemodynamic data at baseline, visit 1 (median 4 months) and visit 2 (median 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Sulica, Roxana, Sangli, Swathi, Chakravarti, Aloke, Steiger, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378454/
https://www.ncbi.nlm.nih.gov/pubmed/30638432
http://dx.doi.org/10.1177/2045894019826944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378454/
https://www.ncbi.nlm.nih.gov/pubmed/30638432
http://dx.doi.org/10.1177/2045894019826944

Ejemplares similares